MoneyWorks4Me

Guj. Themis Biosyn - Quaterly Results

10 Aug 2023 Evaluate
A fair growth of 10.33% in the revenue at Rs. 495.88 millions was reported in the June 2023 quarter as compared to Rs. 449.44 millions during year-ago period.Net profit declined -0.28% to Rs. 177.21 millions from Rs. 177.71 millions.Operating Profit saw a handsome growth to 245.81 millions from 242.02 millions in the quarter ended June 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 495.88 449.44 10.33 495.88 449.44 10.33 1489.73 1148.54 29.71
Other Income 10.75 14.23 -24.46 10.75 14.23 -24.46 60.24 40.50 48.74
PBIDT 245.81 242.02 1.57 245.81 242.02 1.57 802.42 620.96 29.22
Interest 0.25 0.62 -59.68 0.25 0.62 -59.68 2.01 8.28 -75.72
PBDT 245.56 241.40 1.72 245.56 241.40 1.72 800.41 612.68 30.64
Depreciation 7.49 5.70 31.40 7.49 5.70 31.40 25.76 22.33 15.36
PBT 238.07 235.70 1.01 238.07 235.70 1.01 774.65 590.35 31.22
TAX 60.86 57.99 4.95 60.86 57.99 4.95 194.96 154.10 26.52
Deferred Tax 0.96 -1.92 -150.00 0.96 -1.92 -150.00 2.55 0.72 254.17
PAT 177.21 177.71 -0.28 177.21 177.71 -0.28 579.69 436.25 32.88
Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00
PBIDTM(%) 49.57 53.85 -7.95 49.57 53.85 -7.95 53.86 54.07 -0.37
Peers
Company Name CMP
Sun Pharma. Inds. 1866.00
Dr. Reddys Labs. 1172.05
Cipla 1372.25
Lupin 2092.00
Zydus Lifesciences 1137.35
View more..